Consensus Acelyrin, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 01:26:57 2024-05-16 pm EDT			5-day change	1st Jan Change
4.745 ^USD	+0.11%		-2.87%	-36.46%

May. 09	Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	CI
May. 09	Acelyrin, Inc. Announces CEO Changes	CI

02fda167b36d.S7lmeKi-ySt_tyB663Zs_2qf2L62FYvGUCrMWEUsBlM.JssUHuz_sV0p9hMP2CUkuAfwr-bRX_qSAR2IFiscMWsm9wIc5cn4TwrhUw~149ebad189e575212898507877414b65

Wells Fargo Raises ACELYRIN's Price Target to $13 From $11, Keeps Equalweight Rating	Mar. 21	MT
Wells Fargo Starts Coverage on ACELYRIN with Equalweight Rating, $11 Price Target	Dec. 13	MT
Citigroup Initiates ACELYRIN at Neutral Rating With $8 Price Target	Dec. 08	MT
Morgan Stanley Adjusts Price Target on ACELYRIN to $13 From $19, Maintains Equal-Weight Rating	Nov. 28	MT
Jefferies Adjusts ACELYRIN Price Target to $12 From $15, Maintains Buy Rating	Nov. 28	MT
Morgan Stanley Downgrades ACELYRIN to Equalweight From Overweight, Cuts Price Target to $19 From $39	23-09-13	MT
Morgan Stanley Adjusts Price Target on Acelyrin to $39 From $29, Maintains Overweight Rating	23-09-05	MT
HC Wainwright Starts Acelyrin at Buy, $44 Price Target	23-09-05	MT
Morgan Stanley Initiates Coverage on Acelyrin With Overweight Rating, $29 Price Target	23-05-30	MT
Jefferies Starts Acelyrin at Buy With $31 Price Target	23-05-30	MT
Piper Sandler Initiates Acelyrin at Overweight With $68 Price Target	23-05-30	MT
TD Cowen Starts Acelyrin at Outperform	23-05-30	MT

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.74 USD

Average target price

22.17 USD

Spread / Average Target

+367.65%

High Price Target

68 USD

Spread / Highest target

+1,334.60%

Low Price Target

8 USD

Spread / Lowest Target

+68.78%